Elsevier

Peptides

Volume 5, Issue 2, March–April 1984, Pages 325-328
Peptides

Biological effects
VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF)

https://doi.org/10.1016/0196-9781(84)90228-6Get rights and content

Abstract

Platelet-activating factor (PAF), a potent endogenous phospholipid released by a variety of mammalian cells, induces platelet activation in vivo and in vitro. Little is known, however, about the physiological modulation of its actions. We have examined the ability of two naturally occurring compounds which stimulate cAMP production, vasoactive intestinal peptide (VIP) and prostacyclin (PGI2), to inhibit PAF-induced platelet aggregation and secretion in vitro. Washed, [3H]serotonin-labeled, rabbit platelets were incubated 60 sec in the presence of VIP, PGI2 or 3-isobutyl-1-methylxanthine (IBMX) and subsequently stimulated with PAF. In separate studies, cAMP levels were determined in similar aliquots of platelets incubated for 30 sec with VIP, PGI2 or IBMX. VIP, PGI2 and IBMX inhibited platelet aggregation and secretion in a dose-dependent manner. Fifty percent inhibition was achieved at final concentrations of 1.7×10−6M VIP, 3.6×10−6M PGI2 and 6.5×10−5M IBMX. IBMX potentiated the inhibitory effects of VIP and PGI2 on PAF-induced platelet activation. VIP and PGI2 elevated platelet cAMP levels four-fold and 50-fold, respectively, in the presence of 10−3 M IBMX. These findings demonstrate that VIP inhibits PAF-induced platelet activation, with a potency comparable to that of PGI2.

References (24)

  • M.L. Blank et al.

    In vivo metabolism of biologically active phospholipids: Ialkyl-2-acetyl-sn-glycerol-3-phosphocholine, a platelet activating-hypotensive phospholipid

    Life Sci

    (1982)
  • G. Brooker et al.

    The Gammaflo, a completely automated radioimmunoassay system

    Science

    (1976)
  • Cited by (53)

    • The specific VPAC2 agonist Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats

      2013, Neuropeptides
      Citation Excerpt :

      Thus, imposing vasodilation and hypotension by VPAC-2 receptor activation (Grant et al., 2006; Ishizuka et al., 1992; Nandha et al., 1991) to the brittle state of GK rat vasculature could have contributed to the negative effect on survival and stroke outcome in our study. Finally, since VIP has been previously reported to potently inhibit platelet-activating factor (PAF) (Cox et al., 1984), the reduced aggregation of thrombocytes by inhibiting the PAF could potentially contribute to brain hemorrhage and will require further scrutiny. In conclusion, our results show that daily systemic administration of the VPAC-2 receptor agonist Bay 55-9837 in type 2 diabetic GK rats, at a dose previously shown to induce insulin secretion, does not produce anti-diabetic efficacy.

    • Immune and inflammatory mechanisms in pulmonary arterial hypertension

      2012, Progress in Cardiovascular Diseases
      Citation Excerpt :

      Other actions may be mediated by inositol trisphosphate synthesis and calcium mobilization. Some of the actions of VIP include, but are not limited to, relaxation of vascular SMC,47 inhibition of PA-SMC proliferation in vitro,48 reduction of pulmonary vasoconstriction induced by endothelin,49 and antithrombotic effects.50 Genetic deletion of VIP results in overexpression of genes that promote pulmonary vascular SMC proliferation, downregulation of antiproliferative genes, as well as upregulation of pro-inflammatory genes51 suggesting a preponderant role of VIP in pulmonary vascular remodeling and inflammatory response in the setting of PAH.

    • Pathogenic mechanisms of pulmonary arterial hypertension

      2008, Journal of Molecular and Cellular Cardiology
      Citation Excerpt :

      Downregulation of vasoactive intestinal peptide (VIP) may also play a pathogenic role. VIP is a pulmonary vasodilator, an inhibitor of proliferation of vascular smooth muscle cells, and an inhibitor of platelet aggregation [152,153]. Decreased concentrations of VIP have been reported in serum and lung tissue of patients with PAH [154].

    View all citing articles on Scopus
    View full text